Virtual Pharma: Lowering Costs for Commercial Products
VxP Pharma Services has recently expanded their services to now provide commercial scale process development and manufacture for multiple dosage forms. Commercially available dosage forms include oral solids, sterile liquids, and transdermal patches, as well as many other hard-to-find dosages.
VxP Pharma CEO - Raymond E. Peck says, “Although the majority of our business comes from development programs for small and large molecules and clinical trials, we have had an increasing number of requests for commercial scale production. Because of this demand, VxP Pharma has decided to expand their capacity in this area to provide a greater number of services and increased level of quality to the pharmaceutical and biotech industries.All of the facilities are based in the United States and have been audited and approved by the US-FDA for cGMP qualified development and commercial scale manufacturing, and domestic/internationally recognized shipping services.”
The Commercial Market
One of the biggest challengesfor a customer is keeping fixed costs down while quickly moving potential drugs through development. Funding has become less readily available in recent years, making companies stretch their dollars as long as possible to keep costs down. That has led us to a widespread adoption of the virtual model like VxP Pharma. The major advantages of utilizing the virtual model approach for commercial manufacturing is faster process development to meet the needs of your dosage form, coupled with a lower total cost compared to the industry average.
Faster Process Development for Commercial Upscale
The pressure to keep operations lean and mean have forced many companies to develop quicker turn-around times for drugs reaching proof-of-concept trials. Preclinical studies are a major obstacle when developing drugs early in development and many Big Pharma companies have too many projects at this stage in the pipeline. Utilizing virtual companies at this stage to help with the early development work can save years of time and will free up the team to focus on more important projects.
Lower Costs with Virtual Pharma
Keeping fixed costs down is a major concern when managing a development project from start to finish. That’s led many mid-size and large pharma and biotech companies to focus on the virtual model. For example, the Chorus group, a division of Eli Lilly& Company, recently publicized their approximate costs when utilizing the virtual model for the majority of their development services. Since Chorus’ inception in 2002, the group has moved many of their drugs from preclinical to proof-of-concept trials at 10% of the previous total costs for the programs. Because of such a vast decrease in spending for R&D and production with the virtual model, many companies are choosing the “virtual model” route.
|share||like 1||report||19 views|